1. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study
- Author
-
Andrew Wiznia, Ann M. Buchanan, Joseph Horton, Keith Nangle, Eugene L. Stewart, Cindy Vavro, Theodore Ruel, Nicole Montañez, and Paul Palumbo
- Subjects
Drug Resistance ,integrase strand transfer inhibitor ,HIV Infections ,HIV Integrase ,Piperazines ,chemistry.chemical_compound ,Heterocyclic Compounds ,Medicine ,Pharmacology (medical) ,Viral ,Child ,Phylogeny ,Pediatric ,education.field_of_study ,biology ,Pharmacology and Pharmaceutical Sciences ,dolutegravir ,Integrase ,Infectious Diseases ,Medical Microbiology ,6.1 Pharmaceuticals ,Dolutegravir ,Hiv 1 integrase ,HIV/AIDS ,Infection ,Heterocyclic Compounds, 3-Ring ,Adolescent ,Pyridones ,Population ,3-Ring ,Microbiology ,Antiviral Agents ,Drug Resistance, Viral ,Oxazines ,Genetics ,Humans ,HIV Integrase Inhibitors ,education ,Genotyping ,Pharmacology ,pediatric HIV ,business.industry ,Evaluation of treatments and therapeutic interventions ,Infant ,Virology ,VIROLOGIC FAILURE ,Regimen ,chemistry ,HIV-1 ,biology.protein ,business ,Pediatric population - Abstract
P1093 is a multicenter, open-label, phase I/II study of pharmacokinetics, safety, and tolerability of dolutegravir plus an optimized background regimen in pediatric participants aged 4 weeks to
- Published
- 2022
- Full Text
- View/download PDF